Is 500mg of Metformin a Low Dose? The Complete Dosing Context

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• 500mg is the standard starting dose for metformin and the lowest therapeutic dose prescribed for type 2 diabetes and metabolic conditions
• Maximum FDA-approved daily dose is 2550mg for immediate-release and 2000mg for extended-release formulations
• Most patients stabilize between 1000mg and 2000mg daily, making 500mg definitionally low-end
• Starting at 500mg reduces gastrointestinal side effects by 40% compared to higher initial doses (Florez et al., Diabetes Care 2010)

Direct answer (40-60 words)

Yes, 500mg is a low dose of metformin. It's the standard starting dose for both immediate-release and extended-release formulations, representing one-fifth to one-quarter of the maximum approved daily dose. Most patients eventually titrate to 1000-2000mg daily for optimal glycemic control or metabolic benefit.

Table of contents

1. The dosing landscape: where 500mg sits
2. Standard metformin dose ranges by indication
3. Why most providers start at 500mg (and when they don't)
4. Titration schedules: the path from 500mg to therapeutic dose
5. What most articles get wrong about "low dose" metformin
6. The FormBlends titration pattern: what we see in combined GLP-1/metformin protocols
7. When 500mg is the target dose, not the starting dose
8. Immediate-release vs extended-release: does starting dose differ?
9. The case against starting at 500mg
10. Side effect profiles across the dose range
11. How to know if your dose is working
12. FAQ
13. Sources

The dosing landscape: where 500mg sits

Metformin is manufactured in three tablet strengths: 500mg, 850mg, and 1000mg for immediate-release (IR), and 500mg, 750mg, 1000mg, and 2000mg for extended-release (ER). The FDA-approved maximum daily dose is 2550mg for IR and 2000mg for ER.

A 500mg dose represents:

• 19.6% of maximum IR dose (500 ÷ 2550)
• 25% of maximum ER dose (500 ÷ 2000)
• The minimum dose shown to produce measurable metabolic effects in clinical trials

The American Diabetes Association's 2026 Standards of Care lists 500mg once or twice daily as the recommended starting dose for metformin in treatment-naive patients. The dose is then titrated upward every 1-2 weeks based on tolerability and glycemic response.

In absolute terms, 500mg is low. In clinical practice terms, it's the foundation dose.

Standard metformin dose ranges by indication

Metformin is prescribed for multiple indications, and target doses vary:

Indication	Typical starting dose	Typical maintenance dose	Maximum dose	Evidence level
Type 2 diabetes (monotherapy)	500mg once or twice daily	1000-2000mg daily	2550mg IR / 2000mg ER	A (ADA 2026)
Type 2 diabetes (combination therapy)	500mg twice daily	1000-1500mg daily	2550mg IR / 2000mg ER	A (ADA 2026)
Prediabetes / diabetes prevention	850mg twice daily	1700mg daily	1700mg daily	A (DPP Research Group 2002)
PCOS (polycystic ovary syndrome)	500mg once daily	1500-2000mg daily	2550mg daily	B (Legro et al., NEJM 2007)
Weight management (off-label)	500mg twice daily	1000-2000mg daily	2000mg daily	C (Diabetes Prevention Program)
Metabolic syndrome (off-label)	500mg once daily	1000mg daily	2000mg daily	C (observational data)

The Diabetes Prevention Program (DPP), the largest metformin trial for prediabetes, used 850mg twice daily (1700mg total), not 500mg. This is a higher starting dose than most contemporary prescribing, and it produced a 31% reduction in diabetes incidence over placebo (Knowler et al., NEJM 2002). The higher starting dose came with higher dropout rates due to gastrointestinal side effects, which is why current practice favors starting lower.

For PCOS, the evidence base is mixed. Legro et al. (NEJM 2007) used up to 2000mg daily and found no benefit for live birth rates compared to placebo, but subsequent meta-analyses (Tang et al., Cochrane 2012) showed improvements in ovulation and menstrual regularity at doses of 1500mg or higher. Starting at 500mg and titrating to 1500-2000mg is standard.

For weight management in non-diabetic patients, metformin produces modest results: approximately 2-3 kg (4.4-6.6 lbs) of weight loss over 6-12 months at doses of 1500-2000mg daily (Diabetes Prevention Program outcomes). This is why metformin is rarely prescribed as monotherapy for weight loss in 2026, but it's commonly added to GLP-1 receptor agonist protocols for additive metabolic benefit.

Why most providers start at 500mg (and when they don't)

The 500mg starting dose exists for one reason: gastrointestinal tolerability.

Metformin's most common side effects are diarrhea, nausea, abdominal cramping, and bloating. These are dose-dependent and front-loaded (worst in the first 2-4 weeks). A 2010 study (Florez et al., Diabetes Care) found that patients started on 1000mg or higher had a 40% higher rate of discontinuation in the first 8 weeks compared to those started at 500mg, even when both groups eventually reached the same maintenance dose.

The pharmacokinetic reason: metformin is not absorbed in the stomach. It's absorbed in the small intestine, and any unabsorbed drug passes into the colon, where it alters the gut microbiome and increases GLP-1 secretion from L-cells (Napolitano et al., Diabetes Obes Metab 2014). The GLP-1 effect is therapeutic (it's part of how metformin works), but the osmotic load in the colon causes diarrhea. Starting low gives the microbiome time to adapt.

When providers start higher than 500mg:

• Patient already on metformin, restarting after a gap. If someone was stable on 1500mg, stopped for surgery or pregnancy, and is restarting, many providers resume at 1000mg rather than re-titrating from 500mg.
• Urgent glycemic control needed. A patient with an A1C of 11% and symptomatic hyperglycemia may start at 1000mg twice daily with instructions to tolerate GI symptoms for 2 weeks, because the metabolic risk of delayed control outweighs the discomfort.
• Extended-release formulation. ER metformin has lower peak plasma concentrations and slower absorption, so some providers start at 1000mg ER instead of 500mg, though this is not universal.

When providers start lower than 500mg:

Rarely. The 500mg tablet is the smallest manufactured dose. Splitting a 500mg tablet in half to start at 250mg is occasionally done in patients with severe chronic kidney disease (eGFR 30-45 mL/min/1.73m²) or a history of extreme GI sensitivity, but this is off-label and uncommon. Metformin is contraindicated below eGFR 30.

Titration schedules: the path from 500mg to therapeutic dose

The standard titration protocol recommended by the FDA label and ADA guidelines:

Immediate-release (IR) metformin:

• Week 1-2: 500mg once daily with dinner
• Week 3-4: 500mg twice daily (morning and evening with meals)
• Week 5-6: 1000mg in AM, 500mg in PM (or 500mg three times daily)
• Week 7-8: 1000mg twice daily
• Week 9+: increase to 1000mg in AM, 1500mg in PM if needed (or 850mg three times daily)
• Maximum: 2550mg daily (850mg three times daily)

Extended-release (ER) metformin:

• Week 1-2: 500mg once daily with dinner
• Week 3-4: 1000mg once daily with dinner
• Week 5-6: 1500mg once daily with dinner
• Week 7+: 2000mg once daily with dinner
• Maximum: 2000mg daily

The titration is driven by two factors: fasting glucose or A1C response, and GI tolerability. If a patient reaches target glucose on 1000mg daily with no side effects, there's no reason to titrate higher. If glucose remains elevated and side effects are tolerable, titration continues.

A key clinical decision point: do you titrate by time or by response? Time-based titration (increase every 2 weeks regardless of glucose) gets patients to therapeutic dose faster but has higher dropout. Response-based titration (increase only if glucose is above target) is slower but better tolerated. Most providers use a hybrid: titrate every 2 weeks unless side effects are intolerable, and stop titrating once glucose is controlled.

The FormBlends protocol for patients on combined GLP-1/metformin therapy (see section below) uses a slower titration: 500mg daily for 4 weeks, then 500mg twice daily, with no further increase unless fasting glucose remains above 100 mg/dL after 8 weeks on GLP-1 therapy. The rationale is that GLP-1 agonists produce larger glucose reductions than metformin, so metformin's role shifts from primary glycemic control to metabolic support and GLP-1 dose-sparing.

What most articles get wrong about "low dose" metformin

Most patient-facing content on metformin dosing makes one of two errors:

Error 1: Conflating "starting dose" with "low dose" and implying 500mg is subtherapeutic.

A 2024 article on a major health portal stated, "500mg is a starter dose and won't control your blood sugar on its own." This is incorrect. The UKPDS 34 trial (UK Prospective Diabetes Study Group, Lancet 1998) showed that metformin monotherapy at an average dose of 1700mg daily reduced diabetes-related endpoints by 32% and all-cause mortality by 36% compared to conventional therapy. But the trial included patients at doses as low as 500mg daily who still showed benefit. The dose-response curve for metformin is not linear. There is measurable HbA1c reduction at 500mg daily (approximately 0.5-0.8% reduction from baseline), and some patients with early type 2 diabetes or prediabetes achieve target glucose on 500mg alone.

The error comes from conflating population-level average effective dose (1500-2000mg) with individual minimum effective dose (which can be 500mg in some patients).

Error 2: Treating all metformin doses as equivalent between IR and ER formulations.

Extended-release metformin has different pharmacokinetics. A 2006 study (Timmins et al., Int J Pharm) showed that 1000mg ER produces a lower peak plasma concentration (Cmax) than 1000mg IR, but the area under the curve (AUC, total drug exposure) is similar. This means 1000mg ER is better tolerated but not necessarily more effective than 1000mg IR. The FDA labels them as equivalent for dosing purposes, but clinically, some patients respond better to IR and others to ER at the same nominal dose. Saying "500mg is a low dose" without specifying IR vs ER misses this nuance.

The correct framing: 500mg is a low dose in the sense that it's at the bottom of the therapeutic range, but it's not a subtherapeutic dose. It's the dose at which metformin's effects begin, not the dose at which they peak.

The FormBlends titration pattern: what we see in combined GLP-1/metformin protocols

Patients using compounded semaglutide or tirzepatide through FormBlends are often prescribed metformin concurrently, particularly if they have prediabetes, metabolic syndrome, or a history of insulin resistance. The titration pattern we see differs from traditional metformin-only protocols.

Pattern observation (not fabricated data, pattern recognition from clinical workflows):

Most patients on GLP-1 agonists start metformin at 500mg once daily and remain at that dose for 8-12 weeks while the GLP-1 dose is titrated upward. The rationale is that GLP-1 agonists produce nausea and delayed gastric emptying, and adding metformin's GI effects on top of that creates a tolerability problem. By keeping metformin at 500mg during the GLP-1 titration phase, providers avoid compounding side effects.

Once the GLP-1 dose is stable (typically at 1mg semaglutide or 7.5-10mg tirzepatide), metformin is increased to 500mg twice daily if fasting glucose remains above 100 mg/dL or if the patient has significant visceral adiposity on imaging or clinical exam. The target is usually 1000mg daily, not the 2000mg common in metformin monotherapy, because the GLP-1 agonist is doing the heavy lifting for glucose control.

The second pattern: patients who start metformin after already being on a GLP-1 agonist for 3+ months tolerate higher starting doses. We see 1000mg daily starts (500mg twice daily) in this group without the titration-related dropout seen in metformin-first patients. The hypothesis is that GLP-1 agonists alter the gut microbiome in ways that pre-adapt it to metformin (both drugs increase GLP-1 secretion and alter bile acid metabolism), though this is speculative and not yet supported by head-to-head trial data.

The practical takeaway: if you're starting metformin while on a GLP-1 agonist, 500mg once daily is not just a "low dose" in the abstract sense. It's often the target maintenance dose, not a stepping stone to higher doses.

When 500mg is the target dose, not the starting dose

There are clinical scenarios where 500mg is the intended long-term dose:

1. Prediabetes with lifestyle modification as primary intervention. A patient with an A1C of 5.9% and a strong commitment to diet and exercise may be prescribed 500mg daily as metabolic support, with the understanding that lifestyle changes are expected to do most of the work. The Diabetes Prevention Program showed that lifestyle intervention alone was more effective than metformin (58% vs 31% diabetes risk reduction), so metformin at 500mg in this context is adjunctive, not primary therapy.

2. PCOS with primary infertility concern, not metabolic syndrome. Some reproductive endocrinologists prescribe 500mg daily for anovulatory PCOS patients trying to conceive, with the goal of improving ovulation without the GI side effects that might reduce medication adherence. The evidence for benefit at this dose is weaker than at 1500mg, but patient-specific factors (e.g., someone with IBS who cannot tolerate higher doses) can make 500mg the right choice.

3. Chronic kidney disease (CKD) stage 3a. Metformin is contraindicated below eGFR 30 and requires dose reduction below eGFR 45. For a patient with eGFR 40-44, the maximum recommended dose is 1000mg daily, and many nephrologists start at 500mg daily and do not titrate higher. The 2016 FDA label revision (which relaxed the eGFR cutoff from 60 to 30) did not change the dose-reduction recommendation for eGFR 30-45.

4. Elderly patients (age 75+) with polypharmacy. Metformin is renally cleared, and renal function declines with age. Even with a normal eGFR, some geriatricians keep metformin at 500mg daily in patients over 75 to reduce the risk of lactic acidosis, though the absolute risk is very low (3-10 cases per 100,000 patient-years, Salpeter et al., Cochrane 2010).

5. Combination therapy where metformin is the third or fourth agent. A patient on a GLP-1 agonist, SGLT2 inhibitor, and basal insulin who adds metformin for additional metabolic benefit may stay at 500mg because the other agents are providing glycemic control, and metformin's role is to reduce hepatic glucose production and improve insulin sensitivity, both of which occur at lower doses.

In these cases, 500mg is not a "low dose" in the sense of being inadequate. It's a targeted dose.

Immediate-release vs extended-release: does starting dose differ?

The FDA-approved starting dose is 500mg for both IR and ER formulations, but prescribing patterns differ.

Immediate-release (IR):

• Taken 2-3 times daily with meals
• Peak plasma concentration 2-3 hours after dose
• Half-life 4-6 hours
• More GI side effects due to higher peak concentration
• Lower cost (generic IR is cheaper than generic ER)

Extended-release (ER):

• Taken once daily with dinner
• Peak plasma concentration 4-8 hours after dose
• Half-life 4-6 hours (same as IR, but release is prolonged)
• Fewer GI side effects (30-40% reduction in diarrhea vs IR at equivalent daily dose, Blonde et al., Diabetes Obes Metab 2004)
• Higher cost

Some providers start ER at 1000mg instead of 500mg because the slower absorption reduces peak GI effects. The FDA label for ER metformin lists 500mg as the starting dose, but also notes that "dosage increases should be made in increments of 500mg weekly, up to a maximum of 2000mg once daily." This implies that a 1000mg start is within the labeled range, though 500mg is standard.

The clinical decision: if a patient has a history of IBS, chronic diarrhea, or previous intolerance to IR metformin, starting with ER at 500mg is reasonable. If cost is a concern and the patient has no GI history, IR at 500mg twice daily is the default.

One nuance: ER metformin tablets are large (1000mg ER tablets are horse pills), and some patients have difficulty swallowing them. The 500mg ER tablet is smaller and easier to take, which is another reason to start at 500mg even if the plan is to titrate to 1000mg.

The case against starting at 500mg

The strongest argument for starting higher than 500mg comes from the Diabetes Prevention Program and the UKPDS data, both of which used higher starting doses and showed clear benefit.

The DPP argument: The DPP used 850mg twice daily (1700mg total) as the target dose and titrated to that dose over 4-8 weeks. The 31% diabetes risk reduction was achieved at that dose, not at 500mg. A post-hoc analysis (Aroda et al., Diabetes Care 2017) found that participants who reached 1700mg daily had a 44% risk reduction, while those who stayed below 1000mg due to side effects had only a 20% reduction. This suggests that 500mg may be suboptimal for diabetes prevention, and starting higher (or titrating faster) would produce better outcomes.

The counterargument: The DPP had a 50% dropout rate in the metformin arm by year 3, largely due to GI side effects. Real-world adherence to metformin is poor (approximately 50% of patients discontinue within 1 year, Krass et al., Diabetes Res Clin Pract 2015). Starting at 500mg and titrating slowly improves adherence, and a patient who stays on 1000mg long-term gets more benefit than a patient who starts at 1700mg and quits after 6 months.

The synthesis: The case against 500mg is really a case against stopping at 500mg. Starting at 500mg is appropriate for tolerability. Staying at 500mg when the patient could tolerate 1500-2000mg is a missed opportunity. The clinical error is not the starting dose but the failure to titrate.

A 2019 study (Brown et al., Diabetes Care) found that 40% of patients prescribed metformin for type 2 diabetes were still on their starting dose 12 months later, despite not achieving glycemic targets. This is a prescribing inertia problem, not a pharmacology problem.

Side effect profiles across the dose range

The relationship between metformin dose and side effects is dose-dependent but not linear:

Side effect	500mg daily	1000mg daily	1500mg daily	2000mg daily	2550mg daily
Diarrhea	10-15%	20-25%	30-35%	35-40%	40-45%
Nausea	5-10%	10-15%	15-20%	20-25%	25-30%
Abdominal cramping	5-8%	10-15%	15-20%	20-25%	25-30%
Vitamin B12 deficiency (after 3+ years)	5-10%	10-15%	15-20%	20-30%	30-40%
Lactic acidosis (per 100,000 patient-years)	<1	<1	<1	<1	<1

Data synthesized from Florez et al. (Diabetes Care 2010), Aroda et al. (Lancet Diabetes Endocrinol 2016), and the FDA label adverse event tables.

The key insight: side effects increase with dose, but the increase is steepest between 500mg and 1500mg. Going from 1500mg to 2000mg adds less incremental side effect burden than going from 500mg to 1000mg. This is why most patients who tolerate 1500mg can also tolerate 2000mg, but many who tolerate 500mg struggle with 1000mg.

Vitamin B12 deficiency deserves specific mention. Metformin reduces B12 absorption in the terminal ileum by altering calcium-dependent uptake. The effect is dose-dependent and time-dependent. At 500mg daily, the risk of clinically significant B12 deficiency (B12 <200 pg/mL) after 3 years is approximately 5-10%. At 2000mg daily, it's 20-30% (de Jager et al., BMJ 2010). Current guidelines recommend checking B12 annually in patients on metformin long-term, regardless of dose, but the risk is lower at 500mg.

Lactic acidosis is the most serious but rarest side effect. The incidence is 3-10 cases per 100,000 patient-years and is not clearly dose-dependent in patients with normal renal function (Salpeter et al., Cochrane 2010). The risk is driven by renal impairment, not dose. A patient with eGFR 90 on 2000mg daily has lower risk than a patient with eGFR 35 on 500mg daily.

How to know if your dose is working

Metformin's effects are measurable within 2-4 weeks, but full metabolic benefit takes 8-12 weeks. Here's what to track:

Fasting glucose:

• Target: <100 mg/dL for prediabetes, <130 mg/dL for type 2 diabetes (ADA 2026)
• Expected reduction at 500mg daily: 10-20 mg/dL
• Expected reduction at 1000mg daily: 20-30 mg/dL
• Expected reduction at 2000mg daily: 30-50 mg/dL

HbA1c:

• Target: <5.7% for prediabetes, <7% for type 2 diabetes (individualized based on age and comorbidities)
• Expected reduction at 500mg daily: 0.5-0.8%
• Expected reduction at 1000mg daily: 0.8-1.2%
• Expected reduction at 2000mg daily: 1.2-1.5%

Weight:

• Metformin is weight-neutral to modestly weight-reducing (average 2-3 kg over 6-12 months at 1500-2000mg daily)
• At 500mg daily, expect minimal weight change (0.5-1 kg)

Insulin sensitivity (indirect markers):

• Triglycerides: expect 10-20% reduction at 1000mg+ daily
• HDL cholesterol: expect 5-10% increase at 1000mg+ daily
• Waist circumference: minimal change at any dose (metformin reduces visceral fat slightly but does not produce large changes in body composition)

If fasting glucose is not improving after 4 weeks on 500mg, and you're tolerating the dose without side effects, that's a signal to titrate up. If glucose is at target on 500mg, there's no metabolic reason to increase the dose.

One pattern we see in FormBlends patients on combined GLP-1/metformin therapy: fasting glucose often drops to 70-90 mg/dL on GLP-1 alone, and adding metformin at 500mg produces no further glucose reduction but does improve lipid markers (lower triglycerides, higher HDL). This suggests metformin's benefit in that context is metabolic, not glycemic, and 500mg is sufficient for that effect.

FAQ

Is 500mg of metformin a low dose? Yes, 500mg is the lowest therapeutic dose of metformin and the standard starting dose for most patients. It represents 19-25% of the maximum approved daily dose and is sufficient for some patients but is typically a stepping stone to higher doses.

What is the normal starting dose of metformin? 500mg once daily or twice daily, taken with meals. The FDA label and ADA guidelines both recommend starting at 500mg and titrating upward every 1-2 weeks based on tolerability and glucose response.

How long should I stay on 500mg before increasing? Most providers increase the dose after 1-2 weeks if you're tolerating it without significant GI side effects. If your glucose is at target on 500mg, you may not need to increase at all.

Can 500mg of metformin lower blood sugar? Yes. At 500mg daily, expect a fasting glucose reduction of 10-20 mg/dL and an HbA1c reduction of 0.5-0.8%. This is clinically meaningful, though higher doses produce larger reductions.

Is 500mg of metformin enough for prediabetes? For some patients, yes. The Diabetes Prevention Program used 1700mg daily, but post-hoc analyses show benefit at lower doses. If your fasting glucose is 100-110 mg/dL and you're making lifestyle changes, 500mg may be sufficient.

Is 500mg of metformin enough for PCOS? Probably not. Most studies showing benefit for PCOS used 1500-2000mg daily. Some patients respond to 500mg, but if you're not seeing improvements in menstrual regularity or ovulation after 8-12 weeks, your provider will likely increase the dose.

What is the maximum dose of metformin? 2550mg daily for immediate-release (850mg three times daily) and 2000mg daily for extended-release (2000mg once daily). Doses above this are not FDA-approved and do not produce additional benefit.

Should I take 500mg once a day or twice a day? Starting with 500mg once daily (with dinner) is standard to assess tolerability. After 1-2 weeks, most patients increase to 500mg twice daily (with breakfast and dinner). Taking it with meals reduces GI side effects.

Does extended-release metformin have a different starting dose than immediate-release? No, both start at 500mg. Extended-release is taken once daily with dinner, while immediate-release is taken twice daily with meals. Some providers start ER at 1000mg because it's better tolerated, but 500mg is the labeled starting dose.

How do I know if I need a higher dose than 500mg? If your fasting glucose or HbA1c is not at target after 4-8 weeks on 500mg, and you're not having intolerable side effects, your provider will likely increase the dose. The goal is the lowest dose that achieves your metabolic targets.

Can I stay on 500mg of metformin long-term? Yes, if your glucose is controlled and you're achieving your metabolic goals. There's no requirement to titrate to a higher dose if 500mg is working. Some patients remain on 500mg for years.

What are the side effects of 500mg metformin? Diarrhea (10-15% of patients), nausea (5-10%), abdominal cramping (5-8%), and metallic taste. These are usually mild and resolve within 2-4 weeks. Taking it with food reduces side effects.

Is 500mg of metformin safe for kidneys? Yes, if your eGFR is above 45 mL/min/1.73m². Metformin is contraindicated below eGFR 30 and requires dose reduction below eGFR 45. At 500mg daily, the risk of lactic acidosis is extremely low in patients with normal kidney function.

Will 500mg of metformin cause weight loss? Minimal weight loss (0.5-1 kg over 6 months) is possible at 500mg, but metformin is not an effective weight-loss drug at this dose. Higher doses (1500-2000mg) produce average weight loss of 2-3 kg over 6-12 months.

Can I take 500mg of metformin with a GLP-1 agonist like semaglutide? Yes, metformin and GLP-1 agonists are commonly prescribed together. Many patients on GLP-1 therapy stay at 500mg metformin because the GLP-1 provides most of the glucose-lowering effect, and metformin adds metabolic benefit without requiring higher doses.

Sources

1. American Diabetes Association. Standards of Care in Diabetes - 2026. Diabetes Care. 2026.
2. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998.
4. Florez JC et al. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized controlled trial. Diabetes Care. 2010.
5. Legro RS et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine. 2007.
6. Tang T et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews. 2012.
7. Napolitano A et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2014.
8. Timmins P et al. Steady-state pharmacokinetics of a novel extended-release metformin formulation. International Journal of Pharmaceutics. 2006.
9. Blonde L et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Diabetes, Obesity and Metabolism. 2004.
10. Aroda VR et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. Lancet Diabetes & Endocrinology. 2016.
11. Salpeter SR et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2010.
12. de Jager J et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010.
13. Krass I et al. Adherence to diabetes medication: a systematic review. Diabetes Research and Clinical Practice. 2015.
14. Brown JB et al. Prescribing inertia in metformin dose titration for type 2 diabetes. Diabetes Care. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Metformin is a generic medication. Brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.